TEUVIJOY Trademark
Trademark Overview
On Monday, March 7, 2022, a trademark application was filed for TEUVIJOY with the United States Patent and Trademark Office. The USPTO has given the TEUVIJOY trademark a serial number of 97299631. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Monday, May 20, 2024. This trademark is owned by Bristol-Myers Squibb Company. The TEUVIJOY trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
General Information
| Serial Number | 97299631 |
| Word Mark | TEUVIJOY |
| Filing Date | Monday, March 7, 2022 |
| Status | 731 - SECOND EXTENSION - GRANTED |
| Status Date | Monday, May 20, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 11, 2023 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 11, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10016 |
Trademark Events
| Event Date | Event Description |
| Thursday, March 10, 2022 | NEW APPLICATION ENTERED |
| Friday, March 11, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, September 29, 2022 | ASSIGNED TO EXAMINER |
| Thursday, September 29, 2022 | NON-FINAL ACTION WRITTEN |
| Thursday, September 29, 2022 | NON-FINAL ACTION E-MAILED |
| Thursday, September 29, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, March 8, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, March 8, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, March 8, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, March 9, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 22, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 11, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 11, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 6, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, August 2, 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, August 2, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, August 2, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, November 22, 2023 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, November 22, 2023 | SOU EXTENSION 1 FILED |
| Wednesday, November 22, 2023 | SOU EXTENSION 1 GRANTED |
| Friday, November 24, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, May 20, 2024 | SOU TEAS EXTENSION RECEIVED |
| Monday, May 20, 2024 | SOU EXTENSION 2 FILED |
| Monday, May 20, 2024 | SOU EXTENSION 2 GRANTED |
| Tuesday, May 21, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, November 25, 2024 | SOU TEAS EXTENSION RECEIVED |
